PanOptica: Dropping in on VEGF

PanOptica VEGF receptor inhibitor avoids the needle for wet AMD

Most of the next generation of treatments for age-related macular degeneration are focusing on reducing or eliminating intravitreal injections, which are burdensome to patients and present safety risks. PanOptica Inc. believes its PAN-90806, a small molecule selective inhibitor of VEGF receptor, will be among the best approaches because it has a validated mechanism, is formulated as an easy-to-use eyedrop and has high bioavailability at the disease site.

Last week, PanOptica

Read the full 695 word article

User Sign In